Embed Size (px)
DESCRIPTION
Indus is an R&D led consumer health company, focussed on producing active ingredients from food-chain raw materials, with clinically proven results. Indus has so far focussed on developing products from fenugreek. Kotak is an investee company of Kotak PE
Citation preview
INDUS BIOTECH PVT LIMITED
Company Report: India-Nutraceuticals-Unlisted 10 APRIL 2014
www.indiabusinessreports.com
COMPANY BACKGROUND
Beginning
Indus is an R&D led consumer health company, focussed on producing active ingredients from food-chain raw materials, with clinically proven results. Indus has so far focussed on developing products from fenugreek.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxx Promoters
The company is widely heldxxxxxxxxxxxxxxxxxxxxxxx
As of Aug’13
XXX
Name No of Shares (%)
1 XX
2 XX
3 XX
4 XX
5 XX
6 XX
7 XX
8 XX
9 XX
10 XX
11 XX
12 XX
Total XX XX
Board of Directors
Name Designation
CMD
Director
Wholetime Director
Director
Address
1, Rahul Residency Off Salunkhe Vihar Road Kondhwa, Pune Maharashtra 020-64785063
Financial Summary
Year ending June 30 FY11 FY12 FY13
Net Sales (Rs mn)
762.4
EBITDA (Rs mn)
494.8
EBITDA Margin (%)
64.9
PAT (Rs mn)
295.8
Net worth (Rs mn)
Debt (Rs mn)
Sales Growth (%)
PAT Growth (%)
ROE (%)
ROCE (%)
D/E (x)
Auditors Price Waterhouse & Co
India-Nutraceuticals-Unlisted Indus Biotech 10 Apr’14
www.indiabusinessreports.com 2
BUSINESS HIGHLIGHTS
XXXX
R&D
XXX
FINANCIAL PERFORMANCE
XXX
India-Nutraceuticals-Unlisted Indus Biotech 10 Apr’14
www.indiabusinessreports.com 3
FUNDING AND FUTURE PLANS
XXXXXXXXX
India-Nutraceuticals-Unlisted Indus Biotech 10 Apr’14
www.indiabusinessreports.com 4
FINANCIAL DETAILS
P&L (Rs mn) FY10 FY11 FY12 FY13
Net Sales
EBITDA
Margin (%)
Interest
Other Income
PBDT
Depreciation
Extraordinary Item
PBT
PAT
PAT Margin (%)
Balance Sheet (Rs mn) FY10 FY11 FY12 FY13
Liabilities
Equity Capital
Reserves
Shareholder Funds
Debt
Deferred tax liability
Other Long Term Lialilites
Total Liabilities
Assets
Fixed Assets (net)
Intangible Assets
Investments
Total Non Current Assets
Inventories
Debtors
Cash
Loans & Advances
Other CA
CL & Provisions
Net Current Assets
Misc Expenses
Total Assets
India-Nutraceuticals-Unlisted Indus Biotech 10 Apr’14
www.indiabusinessreports.com 5
Ratios FY11 FY12 FY13
Growth (%) Sales
PBDIT PBT PAT
Margins (%) PBDIT PAT
Balance Sheet Ratios ROE (%) ROCE (%) D/E (x) Debtors t/o (days)
About India Business Reports India Business Reports (IBR) is an initiative of experienced professionals with comprehensive experience across wide domains – Research, Investment Banking, Private Equity Funding, Consulting, Branding and Marketing. The single minded objective at IBR is to generate insightful reports based on hard facts. Our endeavour is to search for a Big Idea, among seemingly un-connected data points, which has significant strategic relevance. So be it India entry strategies, growth strategies, M&A opportunities or private equity investments, our reports can become a powerful tool in many ways. Our content and expertise is relevant not only for the financial fraternity, but also global MNCs looking to do business with India, and Indian companies looking to fine tune their growth strategies. Disclaimer This note is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. The content in this note is solely for informational purpose and is not a solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this note constitutes investment, legal, accounting and tax advice. India Business Reports or its owner-partners accept no liabilities for any loss or damage of any kind arising out of the use of this note. Contact [email protected]
